3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Pancreatic Neoplasms
3
Triple Negative Breast Neoplasms
1
Thymoma
1
Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
69
Fluorouracil
44
pembrolizumab
43
Oxaliplatin
42
Capecitabine
40
Bevacizumab
37
Leucovorin
36
Irinotecan
31
Cisplatin
27
Nivolumab
24
Paclitaxel
21
Cetuximab
21
Panitumumab
20
130-nm albumin-bound paclitaxel
20
Sorafenib
18
Albumin-Bound Paclitaxel
18
Drug Therapy
15
Docetaxel
15
Cyclophosphamide
15
Radiotherapy
14
Blood Specimen Collection
14
IFL protocol
12
atezolizumab
11
Exercise
11
Taxes
10
budigalimab
9
Erlotinib Hydrochloride
9
trametinib
8
Folfox protocol
8
Carboplatin
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
anetumab ravtansine
×
Gastrointestinal
×
Clear all
NCT03102320
2022-06-30
ARCS-Multi
Bayer
Phase 1
Completed
173 enrolled